Biogen posts much smaller-than-expected sales of new Alzheimer’s drug By Reuters

© Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder

(Reuters) – Biogen Inc (NASDAQ:) fell well short of Wall Street estimates for third-quarter sales of its Alzheimer’s drug Aduhelm on Wednesday, as the drugmaker struggles to sell the treatment to hospitals and get insurers to cover it.

The company recorded $300,000 in sales of the drug, compared to analysts’ average estimates of $10.79 million, according to Refinitiv data.

Biogen has pinned its hopes on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, as it wrestles with increased competition for its main revenue drivers.

However, the $56,000-a-year treatment is facing a slower-than-expected uptake.

Several commercial insurers are waiting for further direction from the U.S. Centers for Medicare & Medicaid Services (CMS) before covering the drug, while some large hospitals have declined to use it.

The CMS will give its initial opinion on whether it will cover Aduhelm’s cost in January 2022, with a final decision expected in April.

Meanwhile, the U.S. Food and Drug Administration’s approval of the treatment using the accelerated approval pathway has been heavily debated, with U.S. lawmakers last month seeking more information related to the approval.

Revenue in the quarter fell to $2.78 billion, from $3.38 billion a year earlier.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link